Dr. John H Strickler
Claim this profileDuke University Medical Center
Area of expertise
Colorectal Cancer
John H Strickler has run 9 trials for Colorectal Cancer. Some of their research focus areas include:
Colon Cancer
John H Strickler has run 7 trials for Colon Cancer. Some of their research focus areas include:
Affiliated Hospitals
Duke University Medical Center
Duke Clinical Research Institute .
Clinical Trials John H Strickler is currently running
Tucatinib + Trastuzumab + Chemotherapy
for Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
Recruiting
2 awards
Phase 3
LY4066434
for Solid Tumors
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.
Recruiting
1 award
Phase 1
4 criteria
More about John H Strickler
Clinical Trial Related
2 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments John H Strickler has experience with
- Trastuzumab
- Tucatinib
- Fluorouracil
- Leucovorin
- Pembrolizumab
- Regorafenib
Breakdown of trials John H Strickler has run
Colorectal Cancer
Colon Cancer
Rectal Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John H Strickler specialize in?
John H Strickler focuses on Colorectal Cancer and Colon Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is John H Strickler currently recruiting for clinical trials?
Yes, John H Strickler is currently recruiting for 6 clinical trials in Durham North Carolina. If you're interested in participating, you should apply.
Are there any treatments that John H Strickler has studied deeply?
Yes, John H Strickler has studied treatments such as Trastuzumab, Tucatinib, Fluorouracil.
What is the best way to schedule an appointment with John H Strickler?
Apply for one of the trials that John H Strickler is conducting.
What is the office address of John H Strickler?
The office of John H Strickler is located at: Duke University Medical Center, Durham, North Carolina 27710 United States. This is the address for their practice at the Duke University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.